Libé R, Borget I, Ronchi CL et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol Off J Eur Soc Med Oncol 26:2119–2125. https://doi.org/10.1093/annonc/mdv329

Article  Google Scholar 

Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol 31:1476–1490. https://doi.org/10.1016/j.annonc.2020.08.2099

Article  CAS  Google Scholar 

Naing A, Meric-Bernstam F, Stephen B et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347. https://doi.org/10.1136/jitc-2019-000347

Article  PubMed  PubMed Central  Google Scholar 

Fassnacht M, Dekkers O, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. https://doi.org/10.1530/EJE-18-0608

Article  PubMed  PubMed Central  Google Scholar 

Haak HR, Hermans J, Velde CJ et al (1994) Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951. https://doi.org/10.1038/bjc.1994.183

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baudin E, Pellegriti G, Bonnay M et al (2001) Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o, p’DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392

Article  CAS  PubMed  Google Scholar 

Hermsen IG, Fassnacht M, Terzolo M et al (2011) Plasma concentrations of o, p’DDD, o, p’DDA, and o, p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851. https://doi.org/10.1210/jc.2010-2676

Article  CAS  PubMed  Google Scholar 

Megerle F, Herrmann W, Schloetelburg W et al (2018) Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 103:1686–1695. https://doi.org/10.1210/jc.2017-02591

Article  PubMed  Google Scholar 

Reidy-Lagunes DL, Lung B, Untch BR et al (2017) Complete responses to mitotane in metastatic adrenocortical carcinoma—a new look at an old drug. Oncologist 22:1102–1106. https://doi.org/10.1634/theoncologist.2016-0459

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hescot S, Slama A, Lombès A et al (2013) Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 20:371–381. https://doi.org/10.1530/ERC-12-0368

Article  CAS  PubMed  Google Scholar 

Sbiera S, Leich E, Liebisch G et al (2015) Mitotane inhibits sterol-o-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 156:3895–3908. https://doi.org/10.1210/en.2015-1367

Article  CAS  PubMed  Google Scholar 

Slooten H, Moolenaar AJ, Seters AP, Smeenk D (1984) The treatment of adrenocortical carcinoma with o, p’-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–53

Article  PubMed  Google Scholar 

Terzolo M, Baudin AE, Ardito A et al (2013) Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol 169:263–270. https://doi.org/10.1530/EJE-13-0242

Article  CAS  PubMed  Google Scholar 

Malandrino P, Al Ghuzlan A, Castaing M et al (2010) Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer 17:797–807. https://doi.org/10.1677/ERC-09-0341

Article  CAS  PubMed  Google Scholar 

Vezzosi D, Do Cao C, Hescot S et al (2018) Time until partial response in metastatic adrenocortical carcinoma long-term survivors. Horm Cancer 9:62–69. https://doi.org/10.1007/s12672-017-0313-6

Article  CAS  PubMed  Google Scholar 

Megerle F, Kroiss M, Hahner S, Fassnacht M (2019) Advanced adrenocortical carcinoma—what to do when first-line therapy fails? Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc 127:109–116. https://doi.org/10.1055/a-0715-1946

Article  CAS  Google Scholar 

Puglisi S, Calabrese A, Basile V et al (2020) Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers 12:740. https://doi.org/10.3390/cancers12030740

Article  PubMed  PubMed Central  Google Scholar 

Pohland RC, Counsell RE (1985) The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicol Appl Pharmacol 77:47–57

Article  CAS  PubMed  Google Scholar 

Gebhardt DO, Moolenaar AJ, Seters AP et al (1992) The distribution of o, p’-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemother Pharmacol 29:331–334

Article  CAS  PubMed  Google Scholar 

Kroiss M, Plonné D, Kendl S et al (2016) Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Eur J Endocrinol 174:343–353. https://doi.org/10.1530/EJE-15-0946

Article  CAS  PubMed  Google Scholar 

Hescot S, Seck A, Guerin M et al (2015) Lipoprotein-free mitotane exerts high cytotoxic activity in adrenocortical carcinoma. J Clin Endocrinol Metab 100:2890–2898. https://doi.org/10.1210/JC.2015-2080

Article  CAS  PubMed  Google Scholar 

Hescot S, Paci A, Seck A et al (2014) The lack of antitumor effects of o, p’DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer 5:312–323. https://doi.org/10.1007/s12672-014-0189-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  Google Scholar 

Sauerbrei W, Perperoglou A, Schmid M et al (2020) State of the art in selection of variables and functional forms in multivariable analysis-outstanding issues. Diagn Progn Res 4:3. https://doi.org/10.1186/s41512-020-00074-3

Article  PubMed  PubMed Central  Google Scholar 

Bogaerts J, Sydes MR, Keat N et al (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer 51:271–281. https://doi.org/10.1016/j.ejca.2014.10.027

Article  PubMed  PubMed Central  Google Scholar 

Decker RA, Elson P, Hogan TF et al (1991) Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110:1006–1013

CAS  PubMed  Google Scholar 

Williamson SK, Lew D, Miller GJ et al (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 88:1159–1165

Article  CAS  PubMed  Google Scholar 

Baudin E, Endocrine Tumor Board of Gustave Roussy (2015) Adrenocortical carcinoma. Endocrinol Metab Clin North Am 44:411–434. https://doi.org/10.1016/j.ecl.2015.03.001

Article  PubMed  Google Scholar 

Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197. https://doi.org/10.1056/NEJMoa1200966

Article  CAS